Amylin jumps on diabetes drug approval

U.S. clearance is a major milestone, but Bydureon faces stiff competition from its fast-selling rival.

By Minyanville Jan 30, 2012 5:22PM
Image: Insurance Money (© Comstock Images/Jupiterimages)By Brett Chase

Shares of Amylin Pharmaceuticals (AMLN) climbed Monday after the biotech company won U.S. approval of its Bydureon diabetes drug.

Amylin shares rose over 17% to close at $14.26. The company's development partner, Alkermes (ALKS), didn't fare as well, ending the day slightly down.

Bydureon is a once-weekly version of Amylin's Byetta, a twice-daily injectable drug used by adults with type 2 diabetes to control blood-sugar levels. Bydureon uses Alkermes' drug-release technology.

Amylin shares had previously slumped as investors grew uneasy about Bydureon's chances of winning approval (the drug was twice rejected by the U.S. Food and Drug Administration) and over concerns whether Bydureon could capture share in a competitive market. In November, Amylin and its previous development partner Eli Lilly (LLY) parted ways, leaving the smaller biotech to fend for itself.

Now that the drug is approved, Amylin has its work cut out for it. The company plans to begin selling the treatment in February. It faces stiff competition from Novo Nordisk's (NVO) already-approved drug Victoza. In a head-to-head study released last year, Amylin and its partners failed to show Bydureon was more effective than Victoza. In fact, the study showed Victoza did a better job of controlling glucose. (See Amylin’s Bydureon Bombs.) Company officials have said the once-weekly dosing of Bydureon still offers an advantage over the daily dosing of Victoza.

"Now we're ready to take this organization to the next level," CEO Daniel Bradbury told investors on a conference call late Friday.  

But some analysts note the uphill battle facing the company. For instance, Amylin also will need to seek a partner to sell the drug outside the U.S. (Bydureon was approved for use in Europe last June.) A partner announcement will be another catalyst for the stock.

"The uncertainty until a potential partnership is announced may serve as an overhang on the stock," William Blair analyst John Sonnier says. He has a "hold" rating on Amylin's stock. He also notes Victoza’s headstart in selling a similar drug and execution risk for Bydureon's sales launch.

"As a small biotechnology company in a highly competitive marketplace, Amylin faces a variety of risks," Sonnier says.

Bydureon is priced to compete with Victoza. At $323.44 for four weeks of therapy, Bydureon's annual cost is around $4,200, a price that falls in the middle of Victoza's annualized price, says ISI Group analyst Mark Schoenebaum.

Victoza's annual cost ranges from $3,400 for low-dose treatments to $5,000 for high doses, according to the analyst.

"We have priced Bydureon in a manner which we believe will enable us to get Bydureon to as many people as possible in as rapid a fashion as possible," Bradbury said.

As part of its approval agreement, Amylin also has to study the safety of Bydureon, particularly for the risk of cancer and cardiovascular disease. Amylin and Lilly said last year that diabetics on Bydureon can actually lower cardiovascular risk. Cancer risk of so-called GLP-1 analogues (the class of drugs to which Bydureon and Victoza belong) has stirred debate in the scientific community.



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
266 rated 2
485 rated 3
660 rated 4
586 rated 5
652 rated 6
640 rated 7
504 rated 8
289 rated 9
159 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.